ImmunityBio Inc logo

ImmunityBio Inc

IBRX
Healthcare|Biotechnology|USA
$8.23
-0.65 (-7.33%)

Upcoming Data Readouts (14)

Jul 2026
Est. completion
P2Head and Neck Cancer
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
NCT06239220n=25
Sep 2026
Est. completion
P1P2Non-muscle Invasive Bladder Cancer
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734n=369
Oct 2026
Est. completion
P2Long COVID
A Study to Assess Anktiva in Patients With Long Covid-19.
NCT07108036n=20
May 2027
Est. completion
P2Platinum-resistant Ovarian Cancer
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
NCT06710288n=20
May 2027
Est. completion
P2Relapsed B-Cell Non Hodgkin Lymphoma
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
NCT07125872n=20
Sep 2027
Est. completion
P1HPV-Related Carcinoma
IBRX-042 In Participants With HPV-Associated Tumors
NCT05976828n=12
Oct 2027
Est. completion
P1Non-Hodgkin Lymphoma Refractory/ Relapsed
Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
NCT06334991n=20
Feb 2028
Est. completion
P1P2NMIBC
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963n=40
Sep 2028
Est. completion
P3NSCLC Stage IV
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
NCT06745908n=507
Dec 2028
Est. completion
P1B-ALL
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
NCT07556757n=10
Aug 2029
Est. completion
P2Non-Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667n=40
Dec 2029
Est. completion
P2Glioblastoma
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
NCT06061809n=34
Jul 2032
Est. completion
P1P2Non-small Cell Lung Cancer Stage IV
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT07355205n=26
Aug 2033
Est. completion
Non Muscle Invasive Bladder Cancer
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT05981131n=6

Awaiting Results (5)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026
P1
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
NCT04340596
May 2026
P1
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT04898543
Oct 2025
P2
Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
NCT02782546
Oct 2025
P2
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT04390399
Oct 2024
P2P3
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
NCT03022825

Recent Press Releases